The VANISH-2 study: A randomized, blinded, multicenter study to evaluate the efficacy and safety of polidocanol endovenous microfoam 0.5% and 1.0% compared with placebo for the treatment of saphenofemoral junction incompetence

Phlebology

Volumn 29, Issue 9, 2014, Pages 608-618

  Todd III, Kenneth L ^a   Wright, DI ^b,c   Gibson, K ^c   Goldman, M ^c   Hertzman, P ^c   Hirsch, S ^c   Hye, R ^c   Isaacs, M ^c   Plaza Ponte, M ^c   Rathbun, S ^c   Rhodes, J ^c   Rosenberg, G ^c   Schul, M ^c   Stanbro, M ^c   Weiss, R ^c  

^a Southeast Vein and Laser Center   (United States)

^b BIOCOMPATIBLES UK LTD   (United Kingdom)

^c NONE

Author keywords

patient reported outcomes; Polidocanol endovenous microfoam; pulmonary embolism; retained coagulum; varicose vein appearance; varicose vein symptoms; varicose veins; venous clinical severity score; venous insufficiency epidemiological and economic study quality of life score; venous thrombus; VVSymQ

Indexed keywords

MACROGOL DERIVATIVE; POLIDOCANOL; SCLEROSING AGENT;

ADOLESCENT; ADULT; AGED; CLINICAL TRIAL; CONTROLLED STUDY; DOPPLER ECHOGRAPHY; DRUG EFFECTS; FEMALE; HUMAN; MALE; MIDDLE AGED; MULTICENTER STUDY; PROCEDURES; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SAPHENOUS VEIN; SCLEROTHERAPY; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; VARICOSE VEINS; VENOUS INSUFFICIENCY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; FEMALE; HUMANS; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; QUALITY OF LIFE; SAPHENOUS VEIN; SCLEROSING SOLUTIONS; SCLEROTHERAPY; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; ULTRASONOGRAPHY, DOPPLER, DUPLEX; VARICOSE VEINS; VENOUS INSUFFICIENCY; YOUNG ADULT;

EID: 84901037458     PISSN: 02683555     EISSN: 14333031     Source Type: Journal    
DOI: 10.1177/0268355513497709     Document Type: Article

References (15)

1. United States Food and Drug Administration. Patient-reported outcome measures: use in medical product development to support labelling claims, http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM193282.pdf (2009, accessed 11 January 2013).
2. Bradbury A, King T, Evans E,et al.Varicose veins symptoms questionnaire: a simple, validated measure of varicose vein symptoms that can be administered daily using a personal digital assistant. Presented at the Society of Vascular Surgery 2012 Annual Meeting, National Harbor, Maryland, USA, 7-9 June 2012.
3. Kingsley J, King T, Orfe E,et al.Capturing the visual impact of varicose veins. Presented at the Society of Vascular Surgery 2012 Annual Meeting, National Harbor, MD, USA, June 7-9 2012.
4. Bush RG,Derrick M,Manjoney D.Major neurological events following foam sclerotherapy.Phlebology. 2008;23:189-192.
5. Regan JD,Gibson KD,Rush JE, et al.Clinical significance of cerebrovascular gas emboli during polidocanol endovenous ultra-low nitrogen microfoam ablation and correlation with magnetic resonance imaging in patients with right-to-left shunt.J Vasc Surg. 2011;53:131-137.
6. Gillet J-L,Guedes JM,Geux J-J, et al.Side-effects and complications of foam sclerotherapy of the great and small saphenous veins: a controlled multicenter prospective study including 1025 patients.Phlebology. 2009;24:131-138.
7. Concato J,Shah N,Horwitz RI.Randomized, controlled trials, observational studies, and the hierarchy or research designs.N Engl J Med. 2000;342:1887-1892.
8. Guide to clinical preventive services: report of the US preventive services task force. 2nd ed. Baltimore: Williams & Wilkins, 1996.Baltimore: Williams & Wilkins; 1996:.
9. Guex JJ,Allaert FA,Gillet JL, et al.Immediate and midterm complications of sclerotherapy: report of a prospective multicenter registry of 12,173 sclerotherapy sessions.Dermatol Surg. 2005;31 (2): 123-128.
10. Sarvananthan T,Shepherd AC,Willenberg T, et al.Neurological complications of sclerotherapy for varicose veins.J Vasc Surg. 2012;55 (1): 243-251.
11. Parsi K.Paradoxical embolism, stroke and sclerotherapy.Phlebology. 2012;27 (4): 147-167.
12. Forlee MV,Grouden M,Moore DJ, et al.Stroke after varicose vein foam injection sclerotherapy.J Vasc Surg. 2006;43:162-164.
13. Bush RG,Derrick M,Manjoney D.Major neurological events following foam sclerotherapy.Phlebology. 2008;23 (4): 189-192.
14. Kearon C,Kahn SR,Agnelli G, et al.Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians evidence-based clinical practice guidelines. 8th ed.Chest. 2008;133:454-545.
15. Regan JD,Gibson KD,Rush JE, et al.Clinical significance of cerebrovascular gas emboli during polidocanol endovenous ultra-low nitrogen microfoam ablation and correlation with magnetic resonance imaging in patients with right-to-left shunt.J Vasc Surg. 2011;53 (1): 131-137.